Global stakeholders come together to collaborate with urgency to address unmet needs for Parkinson’s therapies.Continue reading
Author Archive: Roxan Olivas
Launch of UNITE4TB Partnership Marks a New Era in Tuberculosis Treatment Development
The partnership will accelerate the development of new Tuberculosis (TB) drug regimens as part of the Innovative Medicines Initiative (IMI), a public-private European Research & Development ConsortiumContinue reading
C-Path Announces Health Care Leader Appointment to Board
TUCSON, Ariz., July 8, 2021 — Critical Path Institute (C-Path) today announced the appointment of health care industry leader and active civic involvement pioneer Mara G. Aspinall, MBA, to its Board of Directors.Continue reading
Clinical Technology Expert and Experienced Neuroscientist Join C-Path in Executive Director Roles
Scottie Kern and Dr. Terina N. Martínez Will Both Serve in Dual Positions
TUCSON, Ariz., June 24, 2021 — Critical Path Institute (C-Path) today announced it has named Scottie Kern, as both Executive Director of the Electronic Patient-Reported Outcome (ePRO) Consortium and Associate Director of the Patient-Reported Outcome (PRO) Consortium and Terina N. Martínez, Ph.D., as Executive Director of both the Duchenne Regulatory Science Consortium (D-RSC) and Critical Path to Therapeutics for the Ataxias (CPTA).Continue reading
C-Path Virtual Workshop to Feature Latest Advances in Clinical Trials for T1D
More than 300 Attendees and 20 Speakers Are Expected to Participate in the International Workshop,
June 15-16Continue reading
C-Path Announces Accelerated Data Sharing Collaboration with Tufts Medical Center
FDA Grant Supports Use of Real-World Data to Generate Real-World Evidence in Neonates
TUCSON, Ariz., May 12, 2021 — Critical Path Institute (C-Path) and Tufts Medical Center have announced a joint venture to integrate the first patient-level clinical trial data to generate actionable real-world evidence (RWE) for neonatal drug development, from real-world neonate data (RWD). This activity, funded by a grant from the U.S. Food and Drug Administration (FDA), is being executed through a neonatal pilot project within C-Path’s International Neonatal Consortium (INC). The data sharing collaboration and transfer also marks the fastest on record for C-Path — starting with the Data Contribution Agreement negotiations and receipt of the data in three months’ time this March.Continue reading
C-Path Appoints Quantitative Sciences Expert as New Sr. Vice President
Dr. Jeff Barrett will lead C-Path’s RDCA-DAP initiative focusing on rare disease data sharing and accelerating therapy development.
TUCSON, Ariz. May 6, 2021 — Critical Path Institute (C-Path) today announced the appointment of Jeff Barrett, Ph.D., F.C.P., as Senior Vice President and lead for its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) initiative.Continue reading
C-Path Selects New Leaders of Data Science and Quantitative Medicine
TUCSON, Ariz., April 26, 2021 — Critical Path Institute (C-Path) has named Amanda J. Borens, M.S., as Executive Director of Data Science within C-Path’s Data Collaboration Center (DCC), and Jackson Burton, Ph.D., as Executive Director of C-Path’s Quantitative Medicine Program.Continue reading
C-Path Opens Access to Duchenne Regulatory Science Consortium Database
Database will allow sharing of individual-level data with the goal of accelerating therapy development for Duchenne muscular dystrophy
TUCSON, Ariz., April 22, 2021 — Critical Path Institute (C-Path) announced today that it will open access to the Duchenne Regulatory Science Consortium (D-RSC) database to qualified researchers, through its Rare Disease Cures Accelerator, Data and Analytics Platform (RDCA-DAP®). The D-RSC database includes data from Duchenne muscular dystrophy (DMD) clinical trials, natural history studies and clinical data collections. The contributors of these datasets have given permission for this data to be shared externally to accelerate therapy development for DMD.